Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria

Bibliography

• Anderson K, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaugrand M, Sly WS, Valle D, editors, The metabolic and molecular basis of inherited disease. 8th edition. McGraw-Hill, New York; 2001. p. 2991-3062
   Google Scholar
• Schneider-Yin X, Gouya L, Meier-Weinand A, New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 2000;159:719-25
   PubMed Web of Science ®Google Scholar
• Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Ophanet J Rare Dis 2009;4:19
   PubMed Web of Science ®Google Scholar
• Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 1984;48:105-17
   PubMed Web of Science ®Google Scholar
• Whatley SD, Mason NG, Holme SA, Molecular epidemiology of erythropoietic protoporphyria in the U.K. Br J Dermatol 2010;162:642-6
   PubMed Web of Science ®Google Scholar
• Gouya L, Puy H, Robreau AM, The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 2002;30:27-8
   PubMed Web of Science ®Google Scholar
• Whatley SD, Ducamp S, Gouya L, C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008;83:408-14
   PubMed Web of Science ®Google Scholar
• Piomelli S, Lamola AA, Poh-Fitzpatrick MF, Erythropoietic protoporphyria and lead intoxication: the molecular basis for difference in cutaneous photosensitivity. I. Different rates of disappearance of protoporphyrin from the erythrocytes, both in vivo and in vitro. J Clin Invest 1975;56:1519-27
   PubMed Web of Science ®Google Scholar
• Brun A, Western A, Malik Z, Sandberg S. Erythropoietic protoporphyria: photodynamic transfer of protoporphyrin from intact erythrocytes to other cells. Photochem Photobiol 1990;51:573-7
   PubMed Web of Science ®Google Scholar
• Ibrahim GW, Watson CJ. Enterohepatic circulation and conversion of protoporphyrin to bile pigment in man. Proc Soc Exp Biol Med 1968;127:890-5
   PubMed Web of Science ®Google Scholar
• Afonso SG, Enriquez DS, Batlle AM. The photodynamic and non-photodynamic actions of porphyrins. Braz J Med Biol Res 1999;32:255-66
   PubMed Web of Science ®Google Scholar
• Magnus IA, Jarrett A, Prankerd TA, Rimington C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961;2:448-51
   PubMed Web of Science ®Google Scholar
• Bagdonas S, Ma LW, Iani V, Phototransformations of 5-aminolevulinic acid-induced protoporphyrin IX in vitro: a spectroscopic study. Photochem Photobiol 2000;72:186-92
   PubMed Web of Science ®Google Scholar
• Goldstein BD, Harber LC. Erythropoietic protoporphyria: lipid peroxidation and red cell membrane damage associated with photohemolysis. J Clin Invest 1972;51:892-902
   PubMed Web of Science ®Google Scholar
• Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981;77:13-9
   PubMed Web of Science ®Google Scholar
• Parrish JA, Rosen CF, Gange RW. Therapeutic uses of light. Ann NY Acad Sci 1985;453:354-64
   PubMed Web of Science ®Google Scholar
• Timonen K, Kariniemi AL, Niemi KM, Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol 2000;43:489-97
   PubMed Web of Science ®Google Scholar
• Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 1989;46:671-85
   PubMedGoogle Scholar
• Lim HW. Pathogenesis of photosensitivity in the cutaneous porphyrias. J Invest Dermatol 2005;124:xvi-vii
   PubMed Web of Science ®Google Scholar
• Rufener EA. “... and found no shade”. Coping processes of patients with erythropoietic protoporphyria. Psychother Psychosom Med Psychol 1992;42:339-48
   PubMed Web of Science ®Google Scholar
• Rufener EA. Erythropoietic protoporphyria: a study of its psychosocial aspects. Br J Dermatol 1987;116:703-8
   PubMed Web of Science ®Google Scholar
• Jong CT, Finlay AY, Pearse AD, The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008;159:192-7
   PubMed Web of Science ®Google Scholar
• Wahlin S, Srikanthan N, Hamre B, Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008;14:1340-6
   PubMed Web of Science ®Google Scholar
• Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009;55:84-97
   PubMed Web of Science ®Google Scholar
• Corbett MF, Herxheimer A, Magnus IA, The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 1977;97:655-62
   PubMed Web of Science ®Google Scholar
• Holme SA, Anstey AV, Finlay AY, Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006;155:574-81
   PubMed Web of Science ®Google Scholar
• Wahlin S, Floderus Y, Stal P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med 2010: published online 13 March 2010, DOI: 10.1111/j.1365-2796.2010. 02236.x
   Google Scholar
• Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995;132:956-63
   PubMed Web of Science ®Google Scholar
• Murphy GM, Hawk JL. Erythropoietic protoporphyria advances today, with a special tribute to the late Professor Ian Magnus. Br J Dermatol 2006;155:501-3
   PubMed Web of Science ®Google Scholar
• Rufener EA. Schattenspringen; Krankheitsanpassung bei Menschen mit einer erythropoetischen Protoporphyrie. 1-386. 1990. Universitat Zurich, Philosophische Fakultat I. (Thesis/Dissertation)
   Google Scholar
• Pawliuk R, Tighe R, Wise RJ, Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase. J Invest Dermatol 2005;124:256-62
   PubMed Web of Science ®Google Scholar
• Pawliuk R, Bachelot T, Wise RJ, Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999;5:768-73
   PubMed Web of Science ®Google Scholar
• Poh-Fitzpatrick MB, Wang X, Anderson KE, Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol 2002;46:861-6
   PubMed Web of Science ®Google Scholar
• Rand EB, Bunin N, Cochran W, Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 2006;118:e1896-9
   PubMed Web of Science ®Google Scholar
• Wahlin S, Aschan J, Bjornstedt M, Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 2007;46:174-9
   PubMed Web of Science ®Google Scholar
• Crombie IK. Racial differences in melanoma incidence. Br J Cancer 1979;40:185-93
   PubMed Web of Science ®Google Scholar
• Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979;40:774-81
   PubMed Web of Science ®Google Scholar
• MacKie RM, Bray CA, Hole DJ, Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 2002;360:587-91
   PubMed Web of Science ®Google Scholar
• Healy E, Jordan SA, Budd PS, Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 2001;10:2397-402
   PubMed Web of Science ®Google Scholar
• Makova K, Norton H. Worldwide polymorphism at the MC1R locus and normal pigmentation variation in humans. Peptides 2005;26:1901-8
   PubMed Web of Science ®Google Scholar
• Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005;571:133-52
   PubMed Web of Science ®Google Scholar
• Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67-90
   PubMed Web of Science ®Google Scholar
• Sturm RA, Duffy DL, Box NF, Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann NY Acad Sci 2003;994:348-58
   PubMed Web of Science ®Google Scholar
• Ha T, Naysmith L, Waterston K, Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype. Ann NY Acad Sci 2003;994:339-47
   PubMed Web of Science ®Google Scholar
• Valverde P, Healy E, Jackson I, Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-30
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Boissy RE, Haering VJ, The pigmentary system: physiology and pathophysiology. 2nd edition. Blackwell Publishing Ltd, Malden, Massachusetts; 2006
   Google Scholar
• Bohm M, Wolff I, Scholzen TE, alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005;280:5795-802
   PubMed Web of Science ®Google Scholar
• Song X, Mosby N, Yang J, alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res 2009;22:809-18
   PubMed Web of Science ®Google Scholar
• Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996;63:1-10
   PubMed Web of Science ®Google Scholar
• Cui R, Widlund HR, Feige E, Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007;128:853-64
   PubMed Web of Science ®Google Scholar
• Barsh G, Attardi LD. A healthy tan? N Engl J Med 2007;356:2208-10
   PubMed Web of Science ®Google Scholar
• Khaled M, Larribere L, Bille K, Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis. J Biol Chem 2002;277:33690-7
   PubMed Web of Science ®Google Scholar
• Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol 2006;126:1966-75
   PubMed Web of Science ®Google Scholar
• Palmer JS, Duffy DL, Box NF, Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86
   PubMed Web of Science ®Google Scholar
• April CS, Barsh GS. Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet 2007;3:e9
   PubMed Web of Science ®Google Scholar
• Robinson S, Dixon S, August S, Protection against UVR Involves MC1R-mediated non-pigmentary and pigmentary mechanisms in vivo. J Invest Dermatol 2010;130:1904-13
   PubMed Web of Science ®Google Scholar
• Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res 2009;22:635-44
   PubMed Web of Science ®Google Scholar
• Dong L, Wen J, Pier E, Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res 2010;70:3547-56
   PubMed Web of Science ®Google Scholar
• Kokot A, Metze D, Mouchet N, alpha-Melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 2009;150:3197-206
   PubMed Web of Science ®Google Scholar
• Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006;27:736-49
   PubMed Web of Science ®Google Scholar
• Wikberg JE. Melanocortin receptors: perspectives for novel drugs. Eur J Pharmacol 1999;375:295-310
   PubMed Web of Science ®Google Scholar
• Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006;27:921-30
   PubMed Web of Science ®Google Scholar
• Kadekaro AL, Wakamatsu K, Ito S, Abdel-Malek ZA. Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006;11:2157-73
   PubMed Web of Science ®Google Scholar
• Gantz I, Konda Y, Tashiro T, Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993;268:8246-50
   PubMed Web of Science ®Google Scholar
• Gantz I, Miwa H, Konda Y, Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993;268:15174-9
   PubMed Web of Science ®Google Scholar
• Spencer JD, Schallreuter KU. Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/melanocortin-4 receptor signaling. Endocrinology 2009;150:1250-8
   PubMed Web of Science ®Google Scholar
• Beaumont KA, Shekar SN, Newton RA, Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Hum Mol Genet 2007;16:2249-60
   PubMed Web of Science ®Google Scholar
• Beaumont KA, Shekar SN, Cook AL, Red hair is the null phenotype of MC1R. Hum Mutat 2008;29:E88-94
   PubMedGoogle Scholar
• Krude H, Biebermann H, Luck W, Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155-7
   PubMed Web of Science ®Google Scholar
• Ghanem G, Verstegen J, Libert A, Alpha-melanocyte-stimulating hormone immunoreactivity in human melanoma metastases extracts. Pigment Cell Res 1989;2:519-23
   PubMedGoogle Scholar
• Ghanem G, Verstegen J, De Rijcke S, Studies on factors influencing human plasma alpha-MSH. Anticancer Res 1989;9:1691-6
   PubMed Web of Science ®Google Scholar
• Nagahama M, Funasaka Y, Fernandez-Frez ML, Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi. Br J Dermatol 1998;138:981-5
   PubMed Web of Science ®Google Scholar
• Sheppard JR, Koestler TP, Corwin SP, Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. Nature 1984;308:544-7
   PubMed Web of Science ®Google Scholar
• Lunec J, Pieron C, Thody AJ. MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma. Melanoma Res 1992;2:5-12
   PubMed Web of Science ®Google Scholar
• Bennett DC, Dexter TJ, Ormerod EJ, Hart IR. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986;46:3239-44
   PubMed Web of Science ®Google Scholar
• Abdel-Malek Z, Swope VB, Suzuki I, Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 1995;92:1789-93
   PubMed Web of Science ®Google Scholar
• Murata J, Ayukawa K, Ogasawara M, Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93
   PubMedGoogle Scholar
• Eves P, Haycock J, Layton C, Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003;89:2004-15
   PubMed Web of Science ®Google Scholar
• Eves PC, MacNeil S, Haycock JW. alpha-Melanocyte stimulating hormone, inflammation and human melanoma. Peptides 2006;27:444-52
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer VC, Cheong SC, Chong H, Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505
   PubMed Web of Science ®Google Scholar
• Osawa M, Egawa G, Mak SS, Molecular characterization of melanocyte stem cells in their niche. Development 2005;132:5589-99
   PubMed Web of Science ®Google Scholar
• Fang D, Nguyen TK, Leishear K, A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-37
   PubMed Web of Science ®Google Scholar
• Ackermann J, Frutschi M, Kaloulis K, Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005;65:4005-11
   PubMed Web of Science ®Google Scholar
• Frank NY, Margaryan A, Huang Y, ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33
   PubMed Web of Science ®Google Scholar
• Jiang J, Sharma SD, Nakamura S, The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995;8:314-23
   PubMedGoogle Scholar
• Ugwu SO, Blanchard J, Dorr RT, Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997;18:259-69
   PubMed Web of Science ®Google Scholar
• Bhardwaj R, Hadley ME, Dorr RT, Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I. Pharm Res 2000;17:593-9
   PubMed Web of Science ®Google Scholar
• Sawyer TK, Sanfilippo PJ, Hruby VJ, 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980;77:5754-8
   PubMed Web of Science ®Google Scholar
• Frandberg PA, Muceniece R, Prusis P, Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochem Biophys Res Commun 1994;202:1266-71
   PubMed Web of Science ®Google Scholar
• Yang Y, Dickinson C, Haskell-Luevano C, Gantz I. Molecular basis for the interaction of [Nle4,D-Phe7]melanocyte stimulating hormone with the human melanocortin-1 receptor. J Biol Chem 1997;272:23000-10
   PubMed Web of Science ®Google Scholar
• Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ, Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. FASEB J 2006;20:1561-3
   PubMed Web of Science ®Google Scholar
• Kadekaro AL, Kavanagh R, Kanto H, alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005;65:4292-9
   PubMed Web of Science ®Google Scholar
• Newton RA, Smit SE, Barnes CC, Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells1. Peptides 2005;26:1818-24
   PubMed Web of Science ®Google Scholar
• Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN®, [Nle4, D-Phe7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006;27:388-94
   PubMed Web of Science ®Google Scholar
• Barnetson RS, Ooi TK, Zhuang L, [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78
   PubMed Web of Science ®Google Scholar
• Minder EI. Afamelanotide. Drugs Future 2010;35:365-72
   Web of Science ®Google Scholar
• Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 2009;360:306-7
   PubMed Web of Science ®Google Scholar
• Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 2009;85:1434-9
   PubMed Web of Science ®Google Scholar
• Minder EI, Harms J, Lautenschlager S, A double-blind, randomized, controlled Phase III trial of afamelanotide (an alpha-MSH analogue) in erythropoietic protoporphyria (EPP) – preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP [abstract]. Berzelius symposium 81- Porphyrins and Porphyrias (14 – 18 June Stockholm) 2009: abstract O09. Available from: http://www.svls.se/cs-media/xyz/bz81final.pdf [Last accessed 29 October 2010]
   Google Scholar
• Minder EI, Schneider-Yin X, Minder CE. Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal. Health Qual Life Outcomes 2010;8:60
   PubMed Web of Science ®Google Scholar
• Preliminary results in Clinuvel's Phase III porphyria trial. Melbourne, Australia: Clinuvel Pharmaceuticals Ltd. 2009. Available from: http://clinuvel.com/resources/cmsfiles/pdf/20091221EPPPrelim.pdf [Last accessed 30 October 2010]
   Google Scholar
• Clinuvel reports positive results in phase III porphria (EPP) clinical trial. Melbourne, Australia: Clinuvel Pharmaceuticals Ltd. 2020. Available from: http://clinuvel.com/resources/cmsfiles/pdf/20100713CUV017Results.pdf [Last accessed 22 October 2010]
   Google Scholar
• Wikberg JES. Melanocortin receptors: new oportunities in drug discovery. Expert Opin Ther Pat 2001;11:61-76
   Web of Science ®Google Scholar
• Schioth HB, Chhajlani V, Muceniece R, Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 1996;59:797-801
   PubMed Web of Science ®Google Scholar